GNS Healthcare Study with Pfizer Reveals Discovery of Novel Clinical Risk Factors Driving …

CAMBRIDGE, Mass.–(BUSINESS WIRE)–GNS Healthcare (GNS), a leading precision medicine company that applies causal machine learning technology to match health interventions to individual patients and discover new intervention pathways, today announced publication of a study conducted jointly with leading pharmaceutical company Pfizer Inc. (NYSE: PFE) by the Journal of Diabetes Science and Technology (JDST). The study is unique in its application of causal machine learning technology to transform electronic health records (EHR) data into computer models that revealed the roles of novel clinical risk factors in progression and speed of progression to type 2 diabetes (T2D) and prediabetes. GNS and Pfizer applied the patented GNS machine learning and simulation platform, REFS™ (Reverse Engineering and Forward Simulation), to an aggregated EHR data sample provided by Humedica, an Optum/United Health Group company, retrospectively…


Link to Full Article: GNS Healthcare Study with Pfizer Reveals Discovery of Novel Clinical Risk Factors Driving …